当前位置： SCI文献检索 > Clinical Genitourinary Cancer期刊下所有文献 > Eosinophilic rash secondary to temsirolimus.

Eosinophilic rash secondary to temsirolimus.

Abstract：

:We present a case of a 73-year-old female with metastatic renal cell carcinoma, clear cell histologic subtype, who developed pruritic rash after 2 weeks of 25 mg weekly infusions of temsirolimus. Rash was located on bilateral antecubital areas and posterior knees. Skin biopsy showed spongiotic dermatitis with eosinophils. Based on history and clinical examination, a diagnosis of drug rash secondary to temsirolimus was made. Temsirolimus is a small-molecule inhibitor of the mammalian target of rapamycin (mTOR). Inhibition of mTOR kinase results in cell cycle arrest, antiangiogenesis, and apoptosis. The mechanism of skin toxicity is unknown; however, it can be hypothesized that there is a direct inhibitory effect on signaling pathways that regulate cell growth and tissue repair. The mTOR kinase inhibitor temsirolimus has shown great promise in increasing overall survival in patients with metastatic renal cell carcinoma. Dermatologic toxicities are among the most prevalent and necessitate early recognition and management, in order to maintain quality of life and consistent therapy. The patient presented was initiated on topical clobetasol resulting in rash resolution at a 2-week follow-up visit.

journal_name

Clin Genitourin Cancer

journal_title

Clinical genitourinary cancer

authors

Gandhi M,Kuzel T,Lacouture M

doi

10.3816/CGC.2009.n.019

subject

Has Abstract

pub_date

2009-08-01 00:00:00

pages

E34-6

issue

2

eissn

1558-7673

issn

1938-0682

pii

S1558-7673(11)70026-X

journal_volume

7

pub_type

杂志文章

相关文献

Clinical Genitourinary Cancer文献大全